Nurix Therapeutics Inc. (NRIX)
NASDAQ: NRIX
· Real-Time Price · USD
9.53
-0.31 (-3.15%)
At close: Aug 20, 2025, 3:59 PM
9.72
1.99%
After-hours: Aug 20, 2025, 05:31 PM EDT
-3.15% (1D)
| Bid | 9.4 |
| Market Cap | 728.56M |
| Revenue (ttm) | 88.38M |
| Net Income (ttm) | -207.32M |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | -3.67 |
| Forward PE | -2.77 |
| Analyst | Buy |
| Ask | 10.13 |
| Volume | 506,818 |
| Avg. Volume (20D) | 851,035 |
| Open | 9.91 |
| Previous Close | 9.84 |
| Day's Range | 9.48 - 9.91 |
| 52-Week Range | 8.18 - 29.56 |
| Beta | 2.15 |
About NRIX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NRIX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NRIX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Nurix Therapeutics Inc. is scheduled to release its earnings on
Oct 10, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+14.21%
Nurix Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
8 months ago
+6.78%
Nurix Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a price target of $35.
1 month ago · seekingalpha.com
Nurix Therapeutics Could Disrupt BTK Therapy And Reward InvestorsNRIX's Bexobrutideg shows impressive ORR for refractory CLL/WM. I believe this positions it as a potential best-in-class BTK degrader in a sizable TAM. Nurix Therapeutics also works with other big pha...
